Control of rubella and congentital rubella syndrome (CRS) in developing countries, part 2: Vaccination against rubella

Bulletin of the World Health Organization

Volumn 75, Issue 1, 1997, Pages 69-80

  Robertson, S E ^a   Cutts, F T ^b   Samuel, R ^c,d   Diaz Ortega, J L ^e  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c CHRISTIAN MEDICAL COLLEGE   (India)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Ministry of Health   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

RUBELLA VACCINE;

CONGENITAL RUBELLA SYNDROME; DEVELOPING COUNTRY; HUMAN; INFECTION CONTROL; NEWBORN; NEWBORN DISEASE; REVIEW; RUBELLA; VACCINATION; ADOLESCENT; ADULT; CHILD; FEMALE; INFANT; MALE; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; FEMALE; HUMANS; INFANT; MALE; PREVENTIVE HEALTH SERVICES; RUBELLA; RUBELLA VACCINE;

EID: 0030612350     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Global Programme for Vaccines and Immunization, Expanded Programme on Immunization: immunization policy. Unpublished document WHO/EPI/ GEN/95.03/Rev.1, 1995 (available upon request from Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland).
2. Anderson RM, May RM. Vaccination against rubella and measles: quantitative investigations of different policies. Journal of hygiene, 1983, 90: 259-325.
3. Cutts FT et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bulletin of the World Health Organization, 1997, 75: 55-68.
4. The sex and age distribution of the world populations, the 1994 revision. New York, United Nations, 1994.
5. Global Programme for Vaccines and Immunization: programme report 1994. Unpublished document WHO/GPV/95.1, 1995 (available upon request from Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland).
6. Plotkin SA. Rubella vaccine. In: Plotkin SA, Mortimer EA, eds. Vaccines, 2nd edition. London, W.B. Saunders, 1994.
7. Weibel RE et al. Clinical and laboratory studies of live attenuated RA 27/3 and HPV 77-DE rubella virus vaccines (40931). Proceedings of the Society for Experimental Biology and Medicine, 1980, 165: 44-49.
8. Lerman SJ, Bollinger M, Brunken JM. Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE5 and RA27/3) virus vaccines, singly and in combination. Pediatrics, 1981, 68: 18-22.
9. Robertson CM et al. Serological evaluation of a measles, mumps, and rubella vaccine. Archives of disease in childhood, 1988, 63: 612-616.
10. Singh R et al. Immune response to measles, mumps and rubella vaccine at 9, 12 and 15 months of age. Indian journal of medical research, 1994, 100: 155-159.
11. Schoub BD et al. Measles, mumps and rubella immunization at nine months in a developing country. Pediatric infectious disease journal, 1990, 9: 263-267.
12. Baba K et al. Rubella epidemic in an institution: protective value of live rubella vaccine and serological behavior of vaccinated, revaccinated and naturally immune groups. Biken journal, 1978, 21: 25-31.
13. Balfour HH Jr et al. Rubella viraemia and antibody responses after rubella vaccination and reimmunization. Lancet, 1981, 1: 1078-1080.
14. Greaves WL et al. Clinical efficacy of rubella vaccine. Pediatric infectious disease journal, 1983, 2: 284-286.
15. O'Shea S et al. Persistence of rubella antibody 8-18 years after vaccination. British medical journal, 1984, 288: 1043.
16. Boué A, Nicolas A, Montagnon B. Reinfection with rubella in pregnant women. Lancet, 1971, 1: 1251-1253.
17. Chang T-W, DesRosiers S, Weinstein L. Clinical and serologic studies of an outbreak of rubella in a vaccinated population. New England journal of medicine, 1970, 283: 246-248.
18. Horstmann DM et al. Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic. New England journal of medicine, 1970, 283: 771-778.
19. Cradock-Watson JE. Laboratory diagnosis of rubella: past, present and future. Epidemiology and infection, 1991, 107: 1-15.
20. Morgan-Capner P et al. Detection of rubella-specific lgM in subclinical rubella reinfection in pregnancy. Lancet, 1985, 1: 244-246.
21. Public Health Laboratory Service and National Congenital Rubella Surveillance Programme. Rubella surveillance to December 1990, United Kingdom. Weekly epidemiological record, 1991, 66(30): 217-220.
22. Preblud SR, Alford CA Jr. Rubella. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant, 3rd edition. London, W.B. Saunders, 1990.
23. Sabin AB. Perspectives on current use of some virus vaccines in the USA. Pediatric research, 1979, 13: 674-683.
24. Best JM. Rubella vaccines: past, present and future. Epidemiology and infection, 1991, 107: 17-30.
25. Rubella vaccination during pregnancy - United States, 1971-1988. Morbidity and mortality weekly report, 1989, 38(17): 289-293.
26. Rubella prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and mortality weekly report, 1990, 39(RR-15): 1-18.
27. Howson CP, Fineberg HV. The ricochet of magic bullets: summary of the Institute of Medicine Report, "Adverse effects of pertussis and rubella vaccines". Pediatrics, 1992, 89(2): 318-324.
28. Slater PE et al. Absence of an association between rubella vaccination and arthritis in underimmune postpartum women. Vaccine, 1995, 13(16): 1529-1532.
29. Ray P et al. Retrospective cohort evaluation of chronic rubella vaccine arthropathy. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 4-7 October 1994. Abstract No. 110, 240.
30. Frey T. Report of an international meeting on rubella vaccines and vaccination, 9 August 1993, Glasgow, United Kingdom. Journal of infectious diseases, 1994, 170: 507-509.
31. Expanded Program on Immunization in the Americas. English-speaking Caribbean rubella policy. EPI newsletter, 1993, 15(4): 6.
32. Expanded Program on Immunization in the Americas. PAHO measles laboratory network workshop. EPI newsletter, 1995, 17(4): 1-2.
33. Expanded Programme on Immunization. Immunization in the English-speaking Caribbean. Weekly epidemiological record, 1996, 71: 217-223.
34. Azevedo-Neto RS de et al. Rubella seroepidemiology in a non-immunized population of São Paulo State, Brazil. Epidemiology and infection, 1994, 113: 161-173.
35. Massad E et al. Assessing the efficacy of a mixed vaccination strategy against rubella in São Paulo, Brazil. International journal of epidemiology, 1995, 24(4): 842-850.
36. Report of a measles/rubella epidemiology workshop for the Arabian Peninsula, Kuwait, 9-10 December 1995. Alexandria, WHO Office for the Eastern Mediterranean Region, 1995.
37. Kabiri M, Moattari A. The rubella immunosurveillance of Iranian females: an indication of the emergence of rubella outbreak in Shiraz, Iran. Iranian journal of medical sciences, 1993, 18: 134-137.
38. Expanded Programme on Immunization. Rubella outbreak, Oman. Weekly epidemiological record, 1994, 69(45): 333-336.
39. Saeed AA, Abu-Shagra S, Al-Rasheed R. Congenital rubella syndrome revisited. Saudi medical journal, 1993, 14: 256.
40. Bakasun V, Suzanic-Karnincic J. A rubella outbreak in the Region of Rijeka, Croatia. International journal of epidemiology, 1995, 24: 453-456.
41. Rudnicka H. [Epidemiology of rubella in 1992]. Przeglad epidemiologicnzy (warszawa), 1994, 48: 75-78 (in Polish).
42. Rubella surveillance, United Kingdom. Weekly epidemiological record, 1993, 68(17): 119-120.
43. Fogel A et al. The impact of rubella epidemics on pregnant women, proof for the necessity of pre-marital screening and vaccination. Developments in biological standardization, 1979, 43: 349-353.
44. Brand N et al. Congenital rubella in Israel following the 1978-79 rubella epidemic. Israel journal of medical sciences, 1983, 19: 925-928.
45. Berger SA, Ginsberg GM, Slater PE. Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants. Israel journal of medical sciences, 1990, 26: 74-80.
46. Isacsohn M et al. Surveillance of congenital rubella and the immunity status to rubella in the Jerusalem area. Israel journal of medical sciences, 1983, 19: 929-933.
47. Swartz TA, Hornstein L, Epstein I. Epidemiology of rubella and congenital rubella infection in Israel, a country with a selective immunization programme. Reviews of infectious diseases, 1985, 7(suppl. 1): S42-S46.
48. Danon YL et al. Prevalence of antibodies against measles, mumps and rubella in Israeli young adults. Israel journal of medical sciences, 1992, 28: 733-736.
49. Robertson SE. Report of a visit to Manila and Kuala Lumpur, 30 June-21 July 1990. Upublished document, Geneva, World Health Organization, 1990.
50. Proceedings of the 90th Anniversary Scientific Seminar, Institute for Medical Research, Kuala Lumpur, Malaysia, 23-25 June 1992. Kuala Lumpur, Institute for Medical Research: 85-86.
51. Rubella immunization programme, Singapore. Weekly epidemiological record, 1989, 64(19): 144-145.
52. Chan CM, Tsang HF. Rubella in Hong Kong. Public health and epidemiology bulletin, Department of Health, Hong Kong, 1995, 4(3): 17-20.
53. Miller CL, Miller E, Waight PA. Rubella susceptibility and the continuing risk of infection in pregnancy. British medical journal, 1987, 294: 1277-1278.
54. Orenstein WA et al. The opportunity and obligation to eliminate rubella from the United States. Journal of the American Medical Association, 1984, 251(15): 1988-1994.
55. Smithells R et al. Congenital rubella in Great Britain 1971-1988. Health trends, 1990, 22(2): 73-76.
56. de Spiegelaere M, Dramaix M, Hennart P. Inégalités sociales et prévention: le statut vaccinal des adolescents. Revue d'épidémiologie et de santé publique, 1996, 44: 228-236.
57. Peckham CS, Marshall WC, Dudgeon JA. Rubella vaccination of schoolgirls: factors affecting vaccine uptake. British medical journal, 1977, 1: 760-761.
58. Baxter DN. Control of the congenital rubella syndrome in Jamaica. West Indian medical journal, 1986, 35: 50-54.
59. Prabhakar P et al. Seroprevalence of Toxoplasma gondii, rubella virus, cytomegalovirus, herpes simplex virus (TORCH) and syphilis in Jamaican pregnant women. West Indian medical journal, 1991, 40: 166-169.
60. Expanded Program on Immunization in the Americas. Measles campaign improves anti-rubella coverage. EPI newsletter, 1994, 16(1): 5-6.
61. Robertson SE et al. Preventing rubella: assessing missed opportunities for immunization. American journal of public health, 1987, 77(10): 1347-1349.
62. Cochi SL et al. Congenital rubella syndrome in the United States, 1970-1985: on the verge of elimination. American journal of epidemiology, 1989, 129: 349-361.
63. Lindegren ML et al. Update: rubella and congenital rubella syndrome, 1980-1990. Epidemiologic reviews, 1991, 13: 341-348.
64. de Quadros CA et al. Measles elimination in the Americas: evolving strategies. Journal of the American Medical Association, 1996, 275(3): 224-229.
65. Stevenson J et al. Resurgence of rubella. Lancet, 1996, 347: 980-981.
66. Isacsohn M, Nishmi M, Swartz TA. Rubella in Jerusalem. 2. Clinical and serologic findings in children with congenital rubella. Israel journal of medical sciences, 1979, 15(1): 17-22.
67. Morgan-Capner P et al. Surveillance of antibody to measles, mumps, and rubella by age. British medical journal, 1988, 297: 770-772.